CTOs on the Move

9 Meters

www.9meters.com

 
9 Meters Biopharma is a clinical-stage company pioneering novel treatments for people with rare digestive diseases, GI conditions with unmet needs, and debilitating disorders in which the biology of the gut is a contributing factor. The Company is advancing vurolenatide, a proprietary Phase 2 long-acting GLP-1 agonist, for short bowel syndrome (SBS), larazotide, a Phase 3 tight junction regulator in non-responsive celiac disease, and several near clinical-stage assets.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.9meters.com
  • 8480 Honeycutt Road Suite 120
    Raleigh, NC USA 27615
  • Phone: 919.275.1933

Executives

Name Title Contact Details

Similar Companies

Mesa Biotech

Accurate. Accessible. Actionable. Simplifying PCR, transforming healthcare.

Fog Pharmaceuticals

FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered `undruggable`.

Biocomputing Platforms

Biocomputing Platforms is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Marsh

Marsh is a global leader in insurance broking and risk management. Marsh helps clients succeed by defining, designing, and delivering innovative industry-specific solutions that help them effectively manage risk. Marsh’s approximately 26,000 colleagues work together to serve clients in more than 130 countries. Marsh is a wholly owned subsidiary of Marsh & McLennan Companies (NYSE:MMC), a global professional services firm offering clients advice and solutions in the areas of risk, strategy, and human capital. With 55,000 employees worldwide and annual revenue exceeding $12 billion, Marsh & McLennan Companies is also the parent company of Guy Carpenter, a global leader in providing risk and reinsurance intermediary services; Mercer, a global leader in talent, health, retirement, and investment consulting; and Oliver Wyman, a global leader in management consulting.

Refuge Biotechnologies

Refuge is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient`s body.